We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas.
- Authors
Yang, Yuelong; Yang, Yunjun; Wu, Xiaoling; Pan, Yi; Zhou, Dong; Zhang, Hongdan; Chen, Yonglu; Zhao, Jiayun; Mo, Zihua; Huang, Biao
- Abstract
Background: The Brain Tumor Reporting and Data System (BT-RADS) category 3 is suitable for identifying cases with intermediate probability of tumor recurrence that do not meet the Response Assessment in Neuro-Oncology (RANO) criteria for progression. The aim of this study was to evaluate the added value of dynamic susceptibility contrast-enhanced perfusion-weighted imaging (DSC PWI) and diffusion-weighted imaging (DWI) to BT-RADS for differentiating tumor recurrence from non-recurrence in postoperative high-grade glioma (HGG) patients with category 3 lesions. Methods: Patients with BT-RADS category 3 lesions were included. The maximal relative cerebral blood volume (rCBVmax) and the mean apparent diffusion coefficient (ADCmean) values were measured. The added value of DSC PWI and DWI to BT-RADS was evaluated by receiver operating characteristic (ROC) curve analysis. Results: Fifty-one of 91 patients had tumor recurrence, and 40 patients did not. There were significant differences in rCBVmax and ADCmean between the tumor recurrence group and non-recurrence group. Compared to BT-RADS alone, the addition of DSC PWI to BT-RADS increased the area under curve (AUC) from 0.76 (95% confidence interval [CI] 0.66–0.84) to 0.90 (95% CI 0.81–0.95) for differentiating tumor recurrence from non-recurrence. The addition of DWI to BT-RADS increased the AUC from 0.76 (95% CI 0.66–0.84) to 0.88 (95% CI 0.80–0.94). The combination of BT-RADS, DSC PWI, and DWI exhibited the best diagnostic performance (AUC = 0.95; 95% CI 0.88–0.98) for differentiating tumor recurrence from non-recurrence. Conclusion: Adding DSC PWI and DWI to BT-RADS can significantly improve the diagnostic performance for differentiating tumor recurrence from non-recurrence in BT-RADS category 3 lesions.
- Subjects
MAGNETIC resonance angiography; RECEIVER operating characteristic curves; DIFFUSION magnetic resonance imaging; BLOOD volume
- Publication
Journal of Neuro-Oncology, 2020, Vol 146, Issue 2, p363
- ISSN
0167-594X
- Publication type
Article
- DOI
10.1007/s11060-019-03387-6